Abstract
AbstractDrug-eluting stent implantation suppresses the excessive proliferation of smooth muscle cells to reduce in-stent restenosis. However, the efficacy of drug-eluting stents remains limited due to delayed reendothelialization, impaired intimal remodeling, and potentially increased late restenosis. Here, we show that a drug-free coating formulation functionalized with tailored recombinant humanized type III collagen exerts one-produces-multi effects in response to injured tissue following stent implantation. We demonstrate that the one-produces-multi coating possesses anticoagulation, anti-inflammatory, and intimal hyperplasia suppression properties. We perform transcriptome analysis to indicate that the drug-free coating favors the endothelialization process and induces the conversion of smooth muscle cells to a contractile phenotype. We find that compared to drug-eluting stents, our drug-free stent reduces in-stent restenosis in rabbit and porcine models and improves vascular neointimal healing in a rabbit model. Collectively, the one-produces-multi drug-free system represents a promising strategy for the next-generation of stents.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference66 articles.
1. Indolfi, C. & Salvatore, D. R. Bioresorbable vascular scaffolds—basic concepts and clinical outcome. Nat. Rev. Cardiol. 13, 719–729 (2016).
2. Mehta, L. S. et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation 140, e30–e66 (2019).
3. Wang, Y., Li, G., Yang, L., Luo, R. & Guo, G. Development of innovative biomaterials and devices for the treatment of cardiovascular diseases. Adv. Mater. 34, 2201971 (2022).
4. Wang, Y. Research and progress of implantable cardiovascular materials and devices. Engineering 7, 1707–1709 (2021).
5. Kleiner, L. W., Wright, J. C. & Wang, Y. Evolution of implantable and insertable drug delivery systems. J. Control. Release 181, 1–10 (2014).